Pulmonx (LUNG)
NASDAQ:LUNG

Pulmonx Stock Analysis & Ratings

LUNG Stock Chart & Stats

Day’s Range$18.34 - $19.45
52-Week Range$15.06 - $45.81
Previous Close$18.52
Volume363.70K
Average Volume (3M)471.91K
Market Cap$713.38M
P/E Ratio-13.7
Beta1.63
Next EarningsAug 02, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)-1.41


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

LUNG FAQ

What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $15.06 and its highest was $45.81 in the past 12 months.
    What is Pulmonx’s market cap?
    Pulmonx’s market cap is $713.38M.
      What is Pulmonx’s price target?
      The average price target for Pulmonx is $30.14. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $37.00 ,the lowest forecast is $23.00. The average price target represents 56.82% Increase from the current price of $19.22.
        What do analysts say about Pulmonx?
        Pulmonx’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
          When is Pulmonx’s upcoming earnings report date?
          Pulmonx’s upcoming earnings report date is Aug 02, 2022 which is in 71 days.
            How were Pulmonx’s earnings last quarter?
            Pulmonx released its earnings results on May 03, 2022. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.371 by -$0.059.
              Is Pulmonx overvalued?
              According to Wall Street analysts Pulmonx’s price is currently Undervalued.
                Does Pulmonx pay dividends?
                Pulmonx does not currently pay dividends.
                What is Pulmonx’s EPS estimate?
                Pulmonx’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Pulmonx have?
                Pulmonx has 37,120,000 shares outstanding.
                  What happened to Pulmonx’s price movement after its last earnings report?
                  Pulmonx reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.371. Following the earnings report the stock price went down -0.434%.
                    Which hedge fund is a major shareholder of Pulmonx?
                    Among the largest hedge funds holding Pulmonx’s share is PRIMECAP Management Co. It holds Pulmonx’s shares valued at 135M.

                      ---

                      Pulmonx Stock Analysis

                      The Pulmonx stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Pulmonx

                      Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.

                      ---
                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis